Greg Lea should have a UC Irvine doctor at his 4PM presentation. Dana Point is very close to Irvine. This is a make or break conference for ETRM. Many more analysts are in Dana Point than were in Boston for Knudson's recent subpar performance.
Ade: Jansz did NOT buy 175,000 shares. He already indirectly owned them as previously reported on 5/14/14. Please check your facts before posting.
Whiterain: If you look at one of the slides from the last presentation ETRM actually claims to have patent protection until at least 2023.
The U.S. Food and Drug Administration has placed a hold on enrollment in the ongoing U.S. pivotal trial for the EndoBarrier. The device is a gastric liner from GI Dynamics that is intended to inhibit the absorption of nutrients, thereby providing weight loss and addressing obesity and Type 2 diabetes.
The FDA hold was due to four cases of bacterial infection of the liver, or hepatic abscess, in the 325 trial subject population. This is a known adverse event related to use of the EndoBarrier--but it presented at higher rates than expected in the trial. The company had set relative thresholds for an anticipated incident rate of hepatic abscess in the trial; the incident with the fourth patient exceeded that and triggered an analysis.
Ade: In this case I actually agree with your projections. The key element missing from discussions on VBLOC is that future generation devices will be even smaller and wireless. The next 5-10 years will bring amazing partnerships in the medical device field with Apple, Google, Amazon et al.
Inns: Greg Lea is presenting next Tuesday in Dana Point, CA. He has a tendency to be more optimistic than Knudson, so I expect a more upbeat presentation. About seven years ago I owned Encysive and an analyst at the Roth conference in Dana Point gave it a big boost, causing the stock to jump 40% in one day. The price action so unnerved Pfizer that they closed a buyout deal for ENCY in time for the following day's open. Dana Point is beautiful and weather beaten analysts love the Roth event-let's face it, sunshine and warm weather puts analysts in a great mood.
There are platinum union plans that will right now pay for VBLOC. An example is the Dockworkers Union on the West Coast: Zero premiums for members and dependents, zero co-pays! Some union plans even look the other way when members sneak in girlfriends(and sometimes their dependents) and pass them off as spouses.
A slide in yesterday's presentation hinted at Asia as a target. UC Irvine has many contacts in Asia and is fast becoming a world class university.
Sentiment: Strong Buy
Perhaps the flu bug. His breathing seemed labored and there were speaking gaps where he seemed to be struggling to find a particular word. The information presented was good, but Knudson appeared most interested in getting through the presentation. If he was that sick he should have had fireball Hancock make the speech. I was happy that the post-presentation continued online with a number of questions by analysts. In fact, the moderator had to cut off the discussion due to the incoming presentation, with adjournment to another meeting room for more followup questions.
ETRM is so oversold that I expect we close green on Tuesday, perhaps over 1.20; Medtronic is just one of dozens of companies, worldwide, that would have a legitimate interest in partnering or buying ETRM.
This has happened several times recently in AH. A 10 share lowball trade which would not be tolerated in the regular trading hours market, where you can't place a bid far away from the market. Either two confederates orchestrate these 10 share trades AH or even one person might simultaneously put in bid and asks for 10 shares at a lowball price. Someone is playing games.
Thanks Pharm: In my ten years of investing in biotech I have never seen a more oversold or irrationally priced stock price than that of ETRM.
Inns: I agree that we are not getting the whole story, which is there are some serious partner/M&A discussions going on. Did you see the story that came out about heart transplant surgeons rejecting more potential donor candidates because of the increase in diabetes and hypertension? VBLOC is a sorely needed alternative therapy. We should get the additional CE mark for hypertension this year, another boost in Europe.
CAPN hit a low of 1.02 on 1/27; they just announced THEIR commercial launch and the stock is currently trading at 5.05, a nearly 400% gain in just 3 weeks. ETRM will have a similar trajectory.
Innsbrooklad: Gold-plated health plans already cover VBLOC. Amazingly, the dockworkers on the West Coast pay zero health plan premiums and have a zero deductible! There are several million members in health plans that make it extremely difficult to NOT get approved for valid treatments like VBLOC.
ETRM has total discretion when and if to use the ATM. No responsible CEO and board of directors would sell shares prematurely at a near yearly low when immediate cash is NOT NEEDED.